Body mass index (BMI) is a main indicator of obesity and its association with breast cancer is well established. However, little is known in the metastatic setting, especially in HER2-positive patients. We assessed the influence of BMI on clinical outcomes of patients treated with pertuzumab and/or trastuzumab emtansine (T-DM1) for HER2+ metastatic breast cancer (mBC). BMI was addressed as a categorical variable, being classified on the basis of the following ranges, that is, 18.5–24.9, 25–29.9, and 30.0–34.9, namely, normal weight, overweight, and Class I obesity. The outcomes chosen were progression-free survival to first-line chemotherapy (PFS1) and overall survival (OS). Overall (N = 709), no impact of BMI was observed on PFS1 (p =.15), while BMI ≥ 30 was associated with worse OS (p =.003). In subjects who progressed to first line (N = 575), analyzing data across PFS1 quartiles and strata of disease burden, BMI predicted lower PFS1 in patients within the I PFS1 quartile and with the lowest disease burden (p =.001). Univariate analysis showed a detrimental effect of BMI ≥ 30 on OS for women within the I PFS1 quartile (p =.03). Results were confirmed in multivariate analysis. According to PFS1 quartiles a higher percentage of patients with high BMI and low disease burden progressed within 6 months of therapy. The effect of BMI on prognosis was also confirmed in multivariate analysis of OS for overall population. In our cohort, a BMI ≥ 30 correlated with worse OS in patients with HER2+ mBC who received pertuzumab and/or T-DM1 but had no impact on PFS to first line. BMI predicted worse I PFS1 quartile.
Krasniqi, E., Pizzuti, L., Barchiesi, G., Sergi, D., Carpano, S., Botti, C., et al. (2020). Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence. JOURNAL OF CELLULAR PHYSIOLOGY, 235(11), 7900-7910.
|Citazione:||Krasniqi, E., Pizzuti, L., Barchiesi, G., Sergi, D., Carpano, S., Botti, C., et al. (2020). Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence. JOURNAL OF CELLULAR PHYSIOLOGY, 235(11), 7900-7910.|
|Tipo:||Articolo in rivista - Articolo scientifico|
|Carattere della pubblicazione:||Scientifica|
|Presenza di un coautore afferente ad Istituzioni straniere:||No|
|Titolo:||Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence|
|Autori:||Krasniqi, E; Pizzuti, L; Barchiesi, G; Sergi, D; Carpano, S; Botti, C; Kayal, R; Sanguineti, G; Marchetti, P; Botticelli, A; Marinelli, D; Gamucci, T; Natoli, C; Grassadonia, A; Tinari, N; Tomao, S; Tonini, G; Santini, D; Michelotti, A; Mentuccia, L; Vaccaro, A; Magnolfi, E; Gelibter, A; Magri, V; Cortesi, E; D'Onofrio, L; Cassano, A; Cazzaniga, M; Moscetti, L; Fabbri, A; Scinto, A; Corsi, D; Carbognin, L; Bria, E; La Verde, N; Garufi, C; Di Stefano, P; Mirabelli, R; Veltri, E; Paris, I; Giotta, F; Lorusso, V; Landucci, E; Ficorella, C; Roselli, M; Adamo, V; Ricciardi, G; Russo, A; Valerio, M; Berardi, R; Pistelli, M; Cannita, K; Zamagni, C; Garrone, O; Baldini, E; Livi, L; Meattini, I; Del Medico, P; Generali, D; De Maria, R; Risi, E; Ciliberto, G; Villa, A; Sperduti, I; Mazzotta, M; Barba, M; Giordano, A; Vici, P|
CAZZANIGA, MARINA ELENA [Membro del Collaboration Group]
|Data di pubblicazione:||2020|
|Rivista:||JOURNAL OF CELLULAR PHYSIOLOGY|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.1002/jcp.29445|
|Appare nelle tipologie:||01 - Articolo su rivista|
File in questo prodotto:
|Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and:or trastuzumab .pdf||Articolo principale||Publisher's version||Administrator Richiedi una copia|